New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC скачать в хорошем качестве

New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

We discussed the MARIPOSA trial, an international randomized phase 3 study focusing on patients with common EGFR mutations in metastatic non-small cell lung cancer, specifically exon 19 deletions and L858R mutations. We talked about the study design, including the use of amivantamab—a bispecific antibody targeting EGFR and MET—and lazertinib, a third-generation EGFR TKI. We discussed the unique mechanism of action of these treatments, including their effects on receptor degradation and immune activity. We also highlighted the importance of monitoring CNS disease in this patient population, where over 50% may develop brain metastases. Discover how the Mariposa study's requirement for CNS imaging differs from historical practices and its implications for understanding treatment efficacy and progression-free survival. Tune in for insights that could shape future treatment decisions for patients with EGFR-mutated lung cancer! Don't forget to like, subscribe, and hit the notification bell for more updates on cancer research and treatment advancements! Follow us on social media: •⁠ ⁠X/Twitter:   / oncbrothers   •⁠ ⁠Instagram:   / oncbrothers   •⁠ Website: https://oncbrothers.com/ •⁠ Main Channel:    / @oncologybrothers